/stocks — the workspaceLOADING
All TELO SEC filings, by type → · Earnings date & implied move · Search inside filings
Latest report (10-Q, filed 2026-08-13). Three months to 2026-06-30 against 2025-06-30: Net loss $1.7M, 66.0% smaller than $5.1M. Six months to 2026-06-30 against 2025-06-30: Operating cash used $2.8M, 78.6% larger than $1.6M. Every report →
Telomir Pharmaceuticals, Inc. (TELO) is a pharmaceutical preparations company. Fundamentals from SEC filings; prices are end-of-day.
What’s behind TELO’s latest move — the size, how unusual the volume is, and the catalyst on the tape, explained and cited to the source.
End-of-day bars · delayed, not real-time · data: Databento · studies computed in your browser from these barsCharting by TradingView Lightweight Charts™
Estimates, not targets. The DCF treats free cash flow as cash flow to equity and divides by shares (the common retail shortcut — it skips net debt and a full WACC), so it’s a sanity-check, not a valuation opinion. All inputs are from TELO’s SEC filings; change any assumption above and the numbers update live. Educational only — not investment advice.
Not reported in XBRL for this filer.
A plain-English read on TELO plus an auto-SWOT — built from TELO's SEC filings and market data, every point cited, nothing invented. Educational, not investment advice.
Four AI analysts — a bull, a bear, a risk manager, and a PM — debate TELO using only the SEC-filing and market facts below. Every point cites its evidence; nothing is invented. This is educational research, not investment advice.
Educational only — not financial advice. Data from SEC EDGAR public filings; no live market data is shown. Figures reflect the company's own reported XBRL facts and may lag.
XBRL company facts, SEC EDGAR. TTM = last four reported quarters. Valuation ratios arrive with a price source — we don't fake quotes.
Has TELO been issuing shares? Offering history →
↓ Download the fiscal-year statement table: XLSX · CSV · revenue, income, EPS, cash flow, balance sheet · from SEC XBRL, dated
As filed. We do not recategorize line items. Each chart plots one XBRL concept exactly as TELO tagged it: net income us-gaap:NetIncomeLoss, EPS us-gaap:EarningsPerShareDiluted, period by period; a period the company did not tag on its own is left out, not estimated. A figure that disagrees with the filing is a bug in our extraction, not a policy, and we fix it: report a mismatch.
Projected from TELO's own SEC 8-K filing history — the year-over-year reporting pattern (about 47% land the exact day, about 91% within a week, measured across 4,713 past reports). No analyst estimates and nothing invented, and every confirmed date links to the source it came from, so you can check it yourself. It upgrades the momentTELO files or announces.
Earnings dates are the company's 8-K Item 2.02 filings (SEC). Reactions from Databento EOD.
No lawmaker has disclosed a trade in TELO under the STOCK Act.
Volume against its own history: 53% of its last 252 sessions were lighter than the last one. Volume detail
None of the 5 estimators could run on TELO's filings.
One estimator is a point estimate, not a range, so no band and no valuation label are published for TELO. Below is everything that was checked, so the refusal can be read rather than taken on trust.
Nothing produced a value.
No fiscal year of price history was on record; the historical multiples need 5. No sector peer set is priced for TELO, so sector medians could not fill the gaps.
Every refusal recorded for TELO → · How often we decline, and why →
No tracked institution reported a position in TELO in the latest 13F round.
Every registered fund files its complete portfolio with the SEC. These weights come from those filings, so each one carries the period it describes. Holdings are quarterly and filed in arrears — the figures below are as of 2026-06-30, not today.
| Fund | Weight | As of |
|---|---|---|
| VTI Vanguard Total Stock Market ETF | <0.01% | 2026-06-30 |
Drawn from 39 large US equity funds we scan, not every fund in existence, so a missing fund means we do not scan it rather than that it holds none. Holdings are joined to tickers by issuer name, which does not resolve every position; what that misses is published.
Head office: Miami, Florida, United States
Source: the cover page of Telomir Pharmaceuticals, Inc.’s 10-Q filed 2026-08-13, on EDGAR. Filings checked 2026-11-02. Incorporation is where the company’s charter was filed. It is not where the business operates or earns, which no filing cover states. How this works
No open-market Form 4 buys or sells reported for TELO in the last ~6 months.
1 of the 2 checks that ran found nothing new for TELO; 1 found something. 2 could not run.
Each event check looks back 30 days from the date its own source was stored, read or generated, never from the date this page was built. A check that finds nothing is a measurement of that window, not a forecast, and a check that cannot be dated does not make the claim at all.